İçeriğe geç
akaturk Akademik ölçüm
Giriş yap Kayıt ol

Makale detayı · 2019 · article

Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?

Dergi Cancer Chemotherapy and Pharmacology
ISSN0344-5704
YÖKSİS OpenAlex
Yıl2019
Atıf36OpenAlex
Atıf20Semantic Scholar · 2 etkili
Yüzdelik%68,1
FWCI0,51,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q2
DOI10.1007/s00280-018-3713-6 OpenAlexOpenAlex kaydı

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıCANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Katalog eşleşmesi (ISSN)Cancer Chemotherapy and Pharmacology
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

Özet henüz derlenmedi; DergiPark / OpenAlex kuyruğu işlenince burada görünecek.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

36atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 9 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2024 Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerAtıf 6 · OpenAlex
  2. 2024 Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerAtıf 6 · OpenAlex
  3. 2024 Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerAtıf 6 · OpenAlex
  4. 2024 Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerAtıf 6 · OpenAlex
  5. 2024 Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerAtıf 6 · OpenAlex
  6. 2024 Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerAtıf 6 · OpenAlex
  7. 2021 Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?Atıf 3 · OpenAlex
  8. 2020 Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?Atıf 3 · OpenAlex
  9. 2020 Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?Atıf 3 · OpenAlex

Yazarlar

13
  1. Osman Kostek 1
  2. Muhammet Bekir Hacioglu 2
  3. ABDULLAH SAKİN İSTANBUL MEDİPOL ÜNİVERSİTESİ 3
  4. Tarik Demir 4
  5. Murat Sari 5
  6. Ozlem Ozkul 6
  7. MURAT ARAZ 7
  8. Aysun Fatma Dogan 8
  9. Nazim Can Demircan 9
  10. Sernaz Uzunoglu 10
  11. Irfan Cicin 11
  12. Bulent Erdogan 12
  13. SERNAZ TOPALOĞLU TRAKYA ÜNİVERSİTESİ 13